Pages that link to "Q891968"
Jump to navigation
Jump to search
The following pages link to nabiximols (Q891968):
Displaying 50 items.
- Sativex for Treatment of Chemotherapy Induced Neuropathic Pain (Q61980506) (← links)
- Neurophysiological Study of Sativex in Multiple Sclerosis (MS) Spasticity (Q63319848) (← links)
- A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer (Q63321495) (← links)
- Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer (Q63335100) (← links)
- Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain (Q63335711) (← links)
- Study to Assess Food Effect on Sativex Bioavailability (Q63335870) (← links)
- Sativex Thorough QT/QTc Study (Q63335979) (← links)
- Comparison of Safety, Tolerability and Pharmacokinetics of Medical Grade Cannabis (MGC) Orally Disintegrating Tablets With Buccal Sativex®, in Healthy Adult Volunteers (Q63574664) (← links)
- Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer (Q63817165) (← links)
- Effects of Sativex(Registered Trademark) and Oral THC on Attention, Affect, Working Memory, Reversal Learning, Physiology and Brain Activation (Q63834732) (← links)
- An Study to Investigate the Efficacy of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis (Q63841315) (← links)
- An Investigation of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis Patients (Q63841322) (← links)
- A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis (Q63841334) (← links)
- A Study of Cannabis Based Medicine Extracts and Placebo in Patients With Pain Due to Spinal Cord Injury (Q63842994) (← links)
- A Study to Compare Sublingual Cannabis Based Medicine Extracts With Placebo to Treat Brachial Plexus Injury Pain (Q63842997) (← links)
- A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological Origin (Q63843001) (← links)
- A Study of the Long-term Safety of Sativex Use (Q63843011) (← links)
- A Study of Sativex in the Treatment of Central Neuropathic Pain Due to Multiple Sclerosis (Q63843468) (← links)
- A Study of Sativex® for Relief of Peripheral Neuropathic Pain Associated With Allodynia. (Q64040554) (← links)
- A Study of Sativex® for Relief of Spasticity in Subjects With Multiple Sclerosis. (Q64040600) (← links)
- A Study of Sativex® for Pain Relief of Peripheral Neuropathic Pain, Associated With Allodynia (Q64040852) (← links)
- A Study of Sativex® for Pain Relief Due to Diabetic Neuropathy (Q64040895) (← links)
- Evaluate the Maintenance of Effect After Long-term Treatment With Sativex® in Subjects With Symptoms of Spasticity Due to Multiple Sclerosis (Q64042492) (← links)
- A Parallel Group Study to Compare Sativex® With Placebo in the Treatment of Detrusor Overactivity in Patients With Multiple Sclerosis (Q64046265) (← links)
- Study to Compare the Safety and Tolerability of Sativex® in Patients With Cancer Related Pain (Q64046763) (← links)
- A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy (Q64047019) (← links)
- Fixed or Self-Titrated Dosages of Sativex on Cannabis Users (Q64071422) (← links)
- An Observational Post-Marketing Safety Registry of Sativex® (Q64222477) (← links)
- An Update of Current Cannabis-Based Pharmaceuticals in Pain Medicine (Q64248155) (← links)
- A Study to Assess the Pharmacokinetic (PK) Properties of Sativex® in Patients With Advanced Cancer (Q64393434) (← links)
- A Randomised, Open-label, Three-way Crossover Study to Assess the Pharmacokinetics and Safety of Single Doses of Four Sprays of Sativex® in a Range of Oral pH Environments in Healthy Subjects (Q64606949) (← links)
- Experimental Medicine in ADHD - Cannabinoids (Q64608712) (← links)
- A Safety Study of Sativex Compared With Placebo (Both With Dose-intense Temozolomide) in Recurrent Glioblastoma Patients (Q64626110) (← links)
- A Safety Study of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma (Q64626111) (← links)
- A Study to Evaluate the Efficacy of Sativex in Relieving Symptoms of Spasticity Due to Multiple Sclerosis (Q64645354) (← links)
- Combination of an Investigational Cannabinoid and Methadone for HIV-associated Neuropathy (Q64717013) (← links)
- A Study to Determine the Maintenance of Effect After Long-term Treatment of Sativex® in Subjects With Neuropathic Pain (Q64719068) (← links)
- A Study to Compare the Safety and Tolerability of Sativex® in Patients With Neuropathic Pain. (Q64719170) (← links)
- A Study of the Safety and Effectiveness of Sativex®, for the Relief of Symptoms of Spasticity in Subjects, From Phase B, With Multiple Sclerosis (MS) (Q64719540) (← links)
- (Q65164958) (redirect page) (← links)
- Anesthetic Premedication With a Cannabis Extract (Cannapremed) (Q65351400) (← links)
- A Study to Evaluate the Pharmacokinetics Of Sativex® in Subjects With Severe Renal Impairment or End Stage Renal Disease, Compared to Matched Subjects With Normal Renal Function. (Q65353232) (← links)
- An Study to Evaluate the Effects of Fluconazole on the Pharmacokinetics (PK) of Sativex® in Healthy Subjects With Cannabis Experience. (Q65353257) (← links)
- Assessment of the Single Dose Pharmacokinetics and Tolerability of Sativex in Patients With Impaired Hepatic Function and Healthy Patients (Q65361450) (← links)
- A Safety, Efficacy and Tolerability Study of Sativex for the Treatment of Spasticity in Children Aged 8 to 18 Years (Q65362910) (← links)
- Bioequivalence Assessment of Oral Administration Vs. Oral Spray of a Cannabinoids (Tetrahydrocannabinol and Cannabidiol) (Q65364082) (← links)
- Phase 3, 28-week, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of Nabiximols as an add-on Therapy in Subjects With Spasticity Due to Multiple Sclerosis. (Q65364701) (← links)
- Sativex and Behavioral-relapse Prevention Strategy in Cannabis Dependence (Q65370729) (← links)
- Abuse Potential of Sativex (Q65376843) (← links)
- Study to Evaluate the Effect of Rifampicin, Ketoconazole, and Omeprazole on the Pharmacokinetics of Sativex (Q65376859) (← links)